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S186 Oral PresentationsHowever, malignant disease remained a predictor for lower OS.
(HR53.38(1.37 -7.3 at 95% CI, p5 0.007). In multivariate analy-
sis of OS modeling, comparing mean values acquired only between
day 0 to Day 365, more accelerated thymic recovery in the first year
(.9% of circulating T cells with a RTE phenotype [CD62L+/
CD45RA+]), was the only immune parameter that was associated
with a reduced risk of death at any time point, HR 0.20 (0.07-
0.60, 95%CI), p5 0.004.
Conclusion: Even among children with relatively better preserved
thymus compared to adults, those with more rapid thymic recovery
leading to more robust rise in RTE will have superior clinical out-
come. These findings should spur further research aiming to en-
hance recovery of the central, thymic derived pathway of T cell
generation.SOLID TUMORS
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CMV-SPECIFIC HER2-REDIRECTED T CELLS FOR THE ADOPTIVE IMMU-
NOTHERAPY OF GLIOBLASTOMA
Ahmed, N.1, Salsman, V.S.1, Kew, Y.2, Shaffer, D.1, Powell, S.Z.2,
Grossman, R.G.2, Bollard, C.M.1,2, Heslop, H.E.1,2, Gottschalk, S.1 1Cen-
ter for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX;
2The Methodist Hospital Research Institute, Houston, Texas
Background:We demonstrated that T cells fromGBMpatients en-
gineered to express a HER2-specific chimeric antigen receptor
(CAR) kill autologous HER2 +GBM cells ex vivo, including the
CD133 +GBM stem cell population. In vivo, the adoptive transfer
of HER2-specific T cells resulted in regression of established
GBM in the brain of mice, yet tumors recurred in a number of
treated animals. This limitation in T-cell efficacy is most likely
due to a) limited T-cell persistence in vivo and/or b) tumor antigen
loss variants in treated tumors. Since the majority of GBMs are pos-
itive for CMVpp65 we expressed HER2.CARs in CMV-specific cy-
totoxic T cells (CTLs) to a) enhance their persistence in vivo
following native T-cell receptor (abTCR) engagement with CMV-
antigens and b) improve their antitumor activity by simultaneously
targeting CMV and HER2.
Methods: To study the feasibility of generating CMV CTLs from
GBMpatients, we determined the precursor frequency of CMV-spe-
cific T cells in 12 patients using IFN-g ELIspot assays. To generate
CMV CTL ex vivo, peripheral blood mononuclear cells were trans-
duced with an adenovirus vector; encoding the immunodominant
CMV-pp65 antigen (Ad5f35pp65) then stimulated with autologous
EBV transformed Ad5f35pp65-transduced irradiated lymphoblastic
cell lines (EBV-LCL). CTLs were then transduced with a retroviral
vector encoding a HER2.CAR (FRP5.CD28.z). We detected
the expression of the CAR transgene using flowcytometry. To con-
comitantly identify the CMV-specific T cell population we used
pentamer analysis for CMVpp65. We performed 51Cr-release
assays to characterize the functionality of HER2.CAR CMV.CTLs
ex vivo.
Results:CMV-specific T cells were readily detectable in the blood
of GBM patients as judged by IFN-g secretion after stimulation
with CMVpp65 PepMixes. We were able to generate CTLs
that are specific for CMV through their endogenous ab TCR
and specific for HER2 through the CAR. Approximately 50% of
CMVpp65-specific CTLs expressed HER2.CARs on the cell sur-
face. CMV-specific CTLs expressing the HER2-specific CAR rec-
ognized and killed the HER2-positive GBM cell line (U373) as well
as autologous OKT3-blasted T cells pulsed with CMVpp65 Pep-
Mixes in a standard 4 hour 51Cr-release assays. Neither the
HER2 –ve cell lines nor autologous OKT3-blasted T cells were
killed.
Conclusion: Our data demonstrates the feasibility of generating
CAR expressing CMVpp65-specific CTLs that are functional
against HER2 and CMV expressed in GBM.84
OUTCOMES WITH HIGH DOSE CHEMOTHERAPY AND AUTOLOGOUS
STEM CELL TRANSPLANTATION (ASCT) IN COMPARISON TO CONVEN-
TIONAL CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH HIGH RISK
EWING’S FAMILY TUMORS
Jodele, S.1, Davies, S.M.1, Wagner, L.M.2, Mehta, P.A.1, Bleesing, J.J.1,
Filipovich, A.H.1, Marsh, R.A.1, Jordan, M.B.1, Kim, M.3,
Perentesis, J.P.2 1Cincinnati Childrens Hospital Medical Center
(CCHMC), OH; 2Cincinnati Childrens Hospital Medical Center, OH;
3Cincinnati Childrens Hospital Medical Center, OH
Pediatric patients with high risk Ewing’s family tumors (hrEFT),
relapsed or metastatic at diagnosis, have very poor outcome
with conventional chemotherapy. A steep dose-response curve to
alkylating agents suggests myeloablative chemotherapy as a poten-
tial therapeutic modality, but controversy persists, warranting
additional investigation. We retrospectively reviewed hrEFT
patients treated with conventional therapy (CHEMO) in compari-
son to high dose alkylator-based chemotherapy and autologous
stem cell transplantation (ASCT) treated at a single center.
Thirty-six patients were assigned into 4 groups based on disease
features and therapy received: REL/CHEMO (n5 12), REL/
ASCT (n5 5), MET/CHEMO (n5 14), MET/ASCT (n5 5).
Kaplan-Meier estimator was used to compare event free survival
(EFS) and overall survival (OS). Seven of 10 ASCT patients
received busulfan, melphalan, thiotepa and 3 of 10 received mel-
phalan, carboplatin and etoposide prior to autologous peripheral
blood stem cell rescue. Both regimens included the chemoprotec-
tant amifostine. Patients had complete response (CR), very
good partial response (VGPR) or partial disease response (PR) at
the time of ASCT. REL/CHEMO patients received a variety of
salvage non-high dose chemotherapies. EFS at 1 and 3 years
from 1st relapse were 100% and 53% in REL/ASCT group in com-
parison to 25% and 8% respectively in REL/CHEMO group
(p5 0.0007). OS at 1 and 3 years from diagnosis were 100% and
80% for REL/ASCT group and 92% and 42% respectively in
REL/CHEMO group (p5 0.013). ASCT-related toxicities were
febrile neutropenia and grade 3 mucositis (n5 10), adrenal insuffi-
ciency (n5 4), bacteriemia (n5 1), and herpes zoster reactivation
(n5 3). We did not observe any veno-occlusive disease of liver
(VOD) or graft failure. There were no regimen-related mortalities.
Four of 5 patients are surviving in the REL/ASCT group, and all
are currently disease-free (one after a further relapse) with a median
time from 1st relapse of 3.3 years (range 1.7-8.9). In comparison,
none of the 12 children with relapsed disease treated with chemo-
therapy alone are surviving, with median time from relapse to death
of 1 year (range 0.1-4.8). In patients with metastatic disease at di-
agnosis, the 1-year OS was 75% in MET/ASCT group, and 64%
respectively in MET/CHEMO group (p5 0.79). Our data suggest
ASCT is tolerable and should be considered as therapeutic option
for relapsed patients. Randomized studies are required to support
these observations.STEM CELL BIOLOGY
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SYSTEMIC ADMINISTRATION OF PLEIOTROPHIN INDUCES HEMATOPOI-
ETIC STEM CELL (HSC) REGENERATION IN VIVO
Himburg, H.A., Daher, P., Meadows, S.K., Russell, J.L., Doan, P.,
Chao, N.J., Chute, J.P. Duke University, Durham, NC
The elucidation of bone marrow microenvironmental signals
which promote HSC regeneration in vivo would have important
implications for the treatment of patients undergoing radiation
therapy, chemotherapy and stem cell transplantation. We recently
reported that pleiotrophin, a soluble heparin-binding growth fac-
tor, induced a 10-fold expansion of long-term repopulating HSCs
in culture (Himburg et al. Blood, Nov 2008; 112: 78). Based on
this observation, we hypothesized that PTN might also be a regen-
erative growth factor for HSCs. Here we tested the effect of sys-
temic administration of PTN to mice to determine if PTN could
promote HSC regeneration in vivo following total body irradiation
(TBI). C57Bl6 mice were irradiated with 700 cGy followed by
